Abstract
AbstractOlsalazine sodium is an anti-inflammatory agent used to treat ulcerative colitis. Both British and European Pharmacopoeia list nine process-related impurities in their monographs. Quantification of the impurities in the final synthesized active pharmaceutical ingredient (API) is required to meet the quality standards set by the International Council for Harmonisation (ICH). Both literature reports and commercial vendors for these impurities are few and far between. The present report describes the synthesis, isolation, purification and characterization of these nine pharmacopeial impurities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
